Alfredo Matias Rodríguez Granillo

Dr. Alfredo Matias Rodríguez Granillo

Interventional Cardiology, Sanatorio Otamendi y Miroli, Buenos Aires, Argentina
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2009 in EuroIntervention
Verified
Journal Article
Closed access
ARAlfredo Rodriguez
Alfredo Rodriguez
AMAndrew Maree
Andrew Maree
STSonia Tarragona
Sonia Tarragona
CFCarlos Fernandez-Pereira
Carlos Fernandez-Pereira
OSOmar Santaera
Omar Santaera
GRGranillo R
Granillo R
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

2 April 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
ARAlfredo E Rodriguez
Alfredo E Rodriguez
CFCarlos Fernandez-Pereira
Carlos Fernandez-Pereira
JMJuan Ramon Mieres
Juan Ramon Mieres
AGAlfredo Matias Rodríguez Granillo
Alfredo Matias Rodríguez Granillo
Despite the introduction of drug-eluting stents (DES) significantly improved the efficacy and safety of percutaneous coronary interventions (PCI), particularly in a high-risk group of patients, the gap between PCI with his competitor’s coronary artery bypass surgery (CABG) and/or optimal medical treatment alone was not reduced. In this revision, we highlighted the fact that in recent years landmark randomized studies reported at mid and long-term follow-ups a high incidence of non-cardiac death, cancer incidence, or both in the DES group of patients. The overall incidence of non-cardiac death was significantly higher in the DES vs. the comparator arm: 5.5% and 3.8%, respectively, p = 0.000018, and non-cardiac death appears to be more divergent between DES vs. the comparator at the extended follow-up to expenses of the last one. One of these trials reported five times greater cancer incidence in the DES arm at late follow-up, 5% vs. 0.7% p < 0.0018. We review the potential reason for these unexpected findings, although we can discard that DES biology could be involved in it. Until all these issues are resolved, we propose that DES implantation should be tailored accorded patient age, life expectancy, and lesion complexity.

22 April 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AGAlfredo Matias Rodríguez Granillo
Alfredo Matias Rodríguez Granillo
JMJuan Mieres
Juan Mieres
CFCarlos Fernandez-Pereira
Carlos Fernandez-Pereira
CSCamila Correa Sadouet
Camila Correa Sadouet
JMJose Milei
Jose Milei
OIon behalf of ORCA Investigators
on behalf of ORCA Investigators
Background: In patients with coronary artery disease, bare-metal stents (BMS) are considered a safer but less effective treatment than drug-eluting stents (DES). Oral colchicine therapy may compensate for this limitation of BMS. This randomized trial compared the cost-effectiveness of two different revascularization strategies during percutaneous coronary intervention (PCI). Methods: Between March 2020 and April 2022, 410 patients were randomly treated with PCI with BMS plus colchicine (BMS-CO: 205 patients) or DES (205 patients) The patients in the BMS-CO group received 0.5 mg oral doses of colchicine for 3 months. The primary endpoint was major adverse cardiac and cerebrovascular events (MACEs), defined as the composite of death, myocardial infarction, stroke, or target vessel revascularization (TVR), and the costs of each treatment strategy. The secondary endpoints included the individual components of MACEs. Results: No significant differences were observed in baseline characteristics, and 76% of the patients presented with acute coronary syndromes. The median follow-up period was 36.8 months. Five percent of the patients in the BMS-CO group discontinued study medication. The cumulative incidence of MACEs was not significantly different, with 12.7% in the BMS-CO group and 15.6% in the DES2G group (p = 0.39) as well individual components of the clinical endpoint. The cumulative costs were lower in the BMS-CO group than in the DES2G group (USD 4826.4 ± 2512 vs. USD 5708 ± 3637, p < 0.001). Conclusions: In the 3 years, the DES strategy failed to be cost-saving compared to BMS-CO. However, due to the small sample size, the equivalence in clinical outcomes with both strategies can occur by chance (NCT04382443).

14 June 2023 in Revista Argentina de Cardiologia
Verified
Journal Article
Open access
CSCamila Correa Sadouet
Camila Correa Sadouet
AGAlfredo Matias Rodríguez Granillo
Alfredo Matias Rodríguez Granillo
HJHernán Jensen
Hernán Jensen
RHRicardo Pérez de la Hoz
Ricardo Pérez de la Hoz
HVHéctor Vetulli
Héctor Vetulli
VCValeria Curotto
Valeria Curotto
Background: Hypertensive disorders of pregnancy (HDP) complicate 10% of pregnancies. They are the main cause of maternal mortality and require a multidisciplinary team to address them.Objectives: The aim of this study was to quantify the prevalence and define the characteristics and outcome of HDP in a center with a program focused on its management.Methods: This was a continuous and prospective registry from November 2019 to July 2021 that included all patients with HDP [chronic hypertension (CHT), gestational hypertension (GHT), early-onset preeclampsia (EPE), late preeclampsia (LPE),superimposed preeclampsia (SIPE) and eclampsia] who met the inclusion criteria. Patients without medical coverage that prevented long-term outpatient follow-up at the institution were excluded. Baseline characteristics and evolution, treatment and persistent HT after puerperium were evaluated. The incidence of intrauterine growth retardation (IUGR), pretermdelivery, maternal mortality and neonatal death within the first 28 days of life was analyzed.Results: Among a total f 5825 deliveries/caesarean sections, 152 patients with GHT (37.5%), EPE (19.7%), LPE (38.8%), SIPE (3.3%), and eclampsia (0.6%) who met the inclusion criteria were included in the study. Mean age was 36.4±5.6 years. Aspirin was administered to 38.1% of patients. The most commonly used antihypertensive drugs were labetalol (65.8%) andenalapril (44.1%) during pregnancy and puerperium, respectively. There was no maternal mortality, and neonatal mortality was 3.6%. Persistent HT was 20.0%.Conclusion: Late preeclampsia was the most frequent HDP in the population analyzed. More than half of the patients who developed HDP did not receive preventive treatment with aspirin, showing a deficit in the identification of the population at risk. One in 5 HDP patients remained with CHTN after puerperium. How to cite this article: Correa Sadouet C, Rodríguez Granillo AM, Jensen H, Pérez de la Hoz R, Vetulli H, De All J, et al. Results of a Prospective Registry of Patients with Hypertensive Disorders of Pregnancy in a Center of the City of Buenos Aires. Rev Argent Cardiol 2022;90:124-9. http://dx.doi.org/10.7775/rac.v90.i2.20505

24 April 2023 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
AGAlfredo Matias Rodríguez Granillo
Alfredo Matias Rodríguez Granillo
CSCarolina Salvatori
Carolina Salvatori
FPFabricio Gastón Procopio
Fabricio Gastón Procopio
GBGiuseppe Biondi-Zoccai
Giuseppe Biondi-Zoccai

5 October 2015 in JACC
Verified
Journal Article
Closed access
PDF file
AGAlfredo Matias Rodríguez Granillo
Alfredo Matias Rodríguez Granillo
JMJuan Mieres
Juan Mieres
RSRaul Solerno
Raul Solerno
CFCarlos Fernandez-Pereira
Carlos Fernandez-Pereira
CHCarlos Haiek
Carlos Haiek
ARAlfredo E Rodriguez
Alfredo E Rodriguez